Skip to main content

Lyme Disease

Volume 492: debated on Tuesday 12 May 2009

To ask the Secretary of State for Health what guidance his Department has issued on the treatment of borreliosis. (273621)

Clinical guidelines for the treatment of borreliosis, commonly known as Lyme disease, are provided to general practitioners and other physicians by the Health Protection Agency (HPA) and published on the HPA’s website at:

www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1204031510081?p=1199451958599

The treatment guidelines published by the Infectious Diseases Society of America in 20061 are included within the HPA’s advice, together with published guidance for the diagnosis and treatment of neuroborreliosis2,3.

In addition, the HPA’s Lyme Disease Reference Unit advises clinicians directly on treatment and patient referral as appropriate.

Source:

1 The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Wormser GP, Dattwyler RJ, Shapiro ED, et al. Clinical Infectious Diseases 2006; 43: 1089-34. Available at:

www.journals.uchicago.edu/CID/journal/issues/v43n9/40897/40897.html

2 Halperin JJ, Logigian EL, Finkel MF, Pearl RA. Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease). Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996 46: 619-627.

3 Practice Parameter: Treatment of nervous system Lyme disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. E-published ahead of print on 23 May 2007. Available at:

www.neurology.org/cgi/rapidpdf/0l.wnl.0000265517 .66976.28vl